1. The US regulatory and pharmacopeia response to the global heparin contamination crisis
- Author
-
Pearle Torralba, Moheb Nasr, Elaine Gray, Roger L. Williams, Gyöngyi Gratzl, Edward K. Chess, Kristian Johansen, David A. Keire, Ali Al-Hakim, Anita Y. Szajek, Janet Woodcock, Christian Viskov, Jian Liu, Robert J. Linhardt, Zachary Shriver, Barbara Mulloy, Tina S. Morris, and Wesley E. Workman
- Subjects
0301 basic medicine ,Drug ,Drug Contamination ,media_common.quotation_subject ,Biomedical Engineering ,Bioengineering ,Global Health ,01 natural sciences ,Applied Microbiology and Biotechnology ,Article ,Food and drug administration ,03 medical and health sciences ,Government regulation ,Product Surveillance, Postmarketing ,medicine ,media_common ,Pharmacopoeias as Topic ,Anticoagulant drug ,Heparin ,United States Food and Drug Administration ,business.industry ,010401 analytical chemistry ,Contamination ,Legislation, Drug ,United States ,0104 chemical sciences ,Biotechnology ,030104 developmental biology ,Practice Guidelines as Topic ,Government Regulation ,Molecular Medicine ,Business ,medicine.drug - Abstract
The contamination of the widely used lifesaving anticoagulant drug heparin in 2007 has drawn renewed attention to the challenges that are associated with the characterization, quality control and standardization of complex biological medicines from natural sources. Heparin is a linear, highly sulfated polysaccharide consisting of alternating glucosamine and uronic acid monosaccharide residues. Heparin has been used successfully as an injectable antithrombotic medicine since the 1930s, and its isolation from animal sources (primarily porcine intestine) as well as its manufacturing processes have not changed substantially since its introduction. The 2007 heparin contamination crisis resulted in several deaths in the United States and hundreds of adverse reactions worldwide, revealing the vulnerability of a complex global supply chain to sophisticated adulteration. This Perspective discusses how the US Food and Drug Administration (FDA), the United States Pharmacopeial Convention (USP) and international stakeholders collaborated to redefine quality expectations for heparin, thus making an important natural product better controlled and less susceptible to economically motivated adulteration.
- Published
- 2016